Ajai Chari MD

PubMed

• Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: Results from the phase 1/2 MonumenTAL-1 s...
  Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don Stevens
  Cancer. 2025-07-15
• Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
  Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel
  Nature Genetics. 2025-07-01
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, Amrik Singh Kang, Nikhil Chilakapati
  Blood. 2025-05-13

Journal Articles

• Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma  
  Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

• Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
  Ajai Chari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patie... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib an... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Ope... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Evolution of Multiple Myeloma Patient Management: Managing Today and Preparing for Tomorrow 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation ph... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgro... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all